trial

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

NCTId NCT02431702
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 337 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2019-11-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
337 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2015-07-08
Primary completion
2019-11-12
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
AripiprazoleHaloperidolOlanzapinePaliperidonePerphenazineQuetiapineRisperidone

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

0 total

Linked catalysts

1
A Study to Compare Disease Progression and Modification Following Treatment With — primary completion2019-11-12

Facts & assertions

4 sourced
Enrollment
337
Phase
PHASE3
Primary Completion Date
2019-11-12
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
Haloperidol
drug
Olanzapine
drug
Paliperidone
drug
Perphenazine
drug
Quetiapine
drug
Risperidone
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication